Headquartered in Seattle, Wash., Atossa Genetics (ATOS) reported significant news on 2/7/19 and again on 3/14/19 that the FDA had issued a "Safe To Proceed" letter under the FDA's Expanded Access program granting approval for the use of one of the company's drugs, Endoxifen. The individual breast cancer patient who was treated showed impressive benefits from the Endoxifen drug therapy and these benefits were achieved without the negative side effects of previous therapies.
Please note that these are two separate achievements of a very significant nature: Both